Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a report released on Tuesday, October 24th.
According to Zacks, “Bellicum Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It is focused on discovering and developing cellular immunotherapies for various forms of cancer, including both hematological and solid tumors, as well as orphan inherited blood disorders. The Company’s lead clinical product candidate is BPX-501, an adjunct T-cell therapy in multiple Phase I/II clinical trials. It is also developing BPX-201, a dendritic cell cancer vaccine, which is in a Phase I clinical trial for the treatment of metastatic castrate-resistant prostate cancer. Bellicum Pharmaceuticals, Inc. is based in Houston, Texas. “
A number of other analysts also recently issued reports on the company. BidaskClub downgraded Bellicum Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Thursday, July 6th. Wells Fargo & Company reiterated an “outperform” rating and set a $31.00 target price on shares of Bellicum Pharmaceuticals in a research report on Tuesday, June 27th. Raymond James Financial, Inc. set a $18.00 price target on Bellicum Pharmaceuticals and gave the company a “buy” rating in a research report on Wednesday, August 9th. Jefferies Group LLC restated a “buy” rating and issued a $16.00 price target (down previously from $18.00) on shares of Bellicum Pharmaceuticals in a research report on Thursday, August 10th. Finally, ValuEngine raised Bellicum Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Monday, September 18th. Two equities research analysts have rated the stock with a sell rating, one has issued a hold rating and five have given a buy rating to the stock. The stock presently has an average rating of “Hold” and a consensus target price of $26.20.
Shares of Bellicum Pharmaceuticals (NASDAQ BLCM) opened at $10.38 on Tuesday. The company has a debt-to-equity ratio of 0.23, a quick ratio of 8.34 and a current ratio of 6.08. Bellicum Pharmaceuticals has a 12-month low of $7.41 and a 12-month high of $23.11.
Bellicum Pharmaceuticals (NASDAQ:BLCM) last posted its quarterly earnings data on Tuesday, November 7th. The biopharmaceutical company reported ($0.71) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.74) by $0.03. The company had revenue of $0.13 million during the quarter, compared to analysts’ expectations of $0.03 million. Bellicum Pharmaceuticals had a negative return on equity of 77.16% and a negative net margin of 17,957.31%. Bellicum Pharmaceuticals’s revenue was up 18.2% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.66) EPS. analysts anticipate that Bellicum Pharmaceuticals will post -2.96 earnings per share for the current year.
WARNING: This piece was originally reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this piece on another domain, it was illegally copied and reposted in violation of U.S. and international copyright & trademark law. The correct version of this piece can be viewed at https://www.dispatchtribunal.com/2017/11/12/bellicum-pharmaceuticals-inc-blcm-lifted-to-hold-at-zacks-investment-research.html.
Large investors have recently bought and sold shares of the business. JPMorgan Chase & Co. lifted its holdings in Bellicum Pharmaceuticals by 10.2% in the second quarter. JPMorgan Chase & Co. now owns 2,466,752 shares of the biopharmaceutical company’s stock worth $28,811,000 after acquiring an additional 227,668 shares during the last quarter. Vanguard Group Inc. boosted its holdings in Bellicum Pharmaceuticals by 13.6% during the second quarter. Vanguard Group Inc. now owns 1,206,436 shares of the biopharmaceutical company’s stock worth $14,092,000 after buying an additional 144,854 shares in the last quarter. State Street Corp boosted its stake in Bellicum Pharmaceuticals by 16.6% in the 2nd quarter. State Street Corp now owns 416,966 shares of the biopharmaceutical company’s stock worth $4,872,000 after purchasing an additional 59,321 shares during the period. Northern Trust Corp boosted its stake in Bellicum Pharmaceuticals by 29.5% in the 2nd quarter. Northern Trust Corp now owns 341,555 shares of the biopharmaceutical company’s stock worth $3,989,000 after purchasing an additional 77,760 shares during the period. Finally, Sphera Funds Management LTD. boosted its stake in shares of Bellicum Pharmaceuticals by 25.0% during the 2nd quarter. Sphera Funds Management LTD. now owns 250,000 shares of the biopharmaceutical company’s stock valued at $2,920,000 after buying an additional 50,000 shares during the period. 55.87% of the stock is owned by institutional investors.
About Bellicum Pharmaceuticals
Bellicum Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing cellular immunotherapies for various forms of cancer, including hematological cancers and solid tumors, as well as orphan inherited blood disorders. The Company uses its chemical induction of dimerization (CID) technology platform to engineer and then control components of the immune system.
Get a free copy of the Zacks research report on Bellicum Pharmaceuticals (BLCM)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Bellicum Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellicum Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.